EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation

Jing Lin, Ting Zhang iD, Yibin Zeng, Lirui Tang, Jieyuan Cai iD, Ling Chen, Jiazhen Fang, Yu Chen, Jinluan Li iD

Therapeutic Advances in Medical Oncology · 2026-04 · 18

DOI: 10.1177/17588359261444616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 26.04.2026. Verfasst von Jing Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Clinical Key Specialty Construction Program, Fujian Research and Training Grants for Young and Middleaged Leaders in Healthcare, the Joint Funds for the Innovation of Science and Technology, Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combined radiotherapy and immunotherapy can enhance antitumor efficacy, but its effects on melanoma brain metastases (MBM) remain unclear.

Objectives

To evaluate the intracranial efficacy, safety, and exploratory immune biomarkers of zimberelimab combined with intracranial hypofractionated radiotherapy in patients with MBM.

Methods

Eligible patients were aged 18–75, had an Eastern Cooperative Oncology Group performance status of 0–2 and measurable brain metastases. Patients received 30–50 Gy/5–10 fractions intracranial hypofractionated radiotherapy and two cycles zimberelimab (240 mg every 3 weeks). The primary endpoint was the intracranial objective response rate (ORR). Secondary endpoints included the disease control rate, overall survival, progression-free survival (PFS), quality of life, safety and potential biomarkers. In addition, serum cytokines were profiled and linked to proteomics-based exploratory prognostic model constructed using the UK Biobank dataset.

Results

Between November 2022 and February 2025, 10 patients, with median age 60.5 years, completed the treatment, and their data were analyzed. The median intracranial metastatic lesion size was 2.4 cm (range 1.0–5.9 cm). The intracranial ORR was 70%, and intracranial disease control rate was 90%. The median overall survival and intracranial PFS were both 12 months, while the overall PFS was 10.5 months. The patients’ quality of life improved, without grade ⩾3 treatment-related adverse events. Furthermore, post-treatment increases in selected immune-related biomarkers, such as CXCL9, were descriptively associated with treatment response, and baseline levels showed exploratory associations with survival outcomes.

Conclusion

HFRT plus zimberelimab demonstrated promising intracranial activity, quality of life improvement, and acceptable early safety in patients with MBM and may potentially induce an abscopal antitumor effect. Exploratory immune analyses suggest that baseline immune readiness and therapy-induced immune activation may be associated with treatment benefit.

Design

This was a prospective, single-arm, open-label phase II study.

Trial registration

ChiCTR, ChiCTR2200057001. Registered 25 February 2022 ( https://www.chictr.org.cn/showproj.html?proj=153144 ).

Schlagwörter

Stichwörter der Autor:innen

UK Biobankbrain metastaseshypofractionated radiotherapyimmunotherapymelanoma

Autor:innen und Institutionen

  • Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
  • Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, China.
  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, China.

ORCID-Profile: Ting Zhang, Jieyuan Cai, Jinluan Li

Förderung

  • the National Clinical Key Specialty Construction Program
  • Fujian Research and Training Grants for Young and Middleaged Leaders in Healthcare
  • the Joint Funds for the Innovation of Science and Technology, Fujian Province
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Lin, J., Zhang, T., Zeng, Y., Tang, L., Cai, J., Chen, L., Fang, J., Chen, Y., & Li, J. (2026). Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261444616

Vancouver

Lin J, Zhang T, Zeng Y, Tang L, Cai J, Chen L, et al. Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261444616

BibTeX
@article{Lin2026,
  author = {Lin, Jing and Zhang, Ting and Zeng, Yibin and Tang, Lirui and Cai, Jieyuan and Chen, Ling and Fang, Jiazhen and Chen, Yu and Li, Jinluan},
  title = {Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261444616}
}
Kostenlos starten →